gdc
Submit Your Story
Subscribe

Newsworthy

Breast CancerFDA Approvals, News & UpdatesNewsworthy
Kadcyla Approved for Adjuvant Treatment of HER2-Positive Early Breast Cancer with Residual Invasive Disease
June 2019 Vol 5 No 3 – June 25, 2019
FDA Approvals, News & UpdatesLeukemiaNewsworthy
Tibsovo Approved for First-Line Treatment of Patients with Acute Myeloid Leukemia and IDH1 Mutation
June 2019 Vol 5 No 3 – June 25, 2019
Breast CancerFDA Approvals, News & UpdatesNewsworthy
Piqray New Treatment Approved for Metastatic Breast Cancer and PI3KCA Mutation
June 2019 Vol 5 No 3 – June 25, 2019
Bladder CancerFDA Approvals, News & UpdatesNewsworthy
Balversa First Targeted Drug Approved for Metastatic Bladder Cancer with FGFR Genetic Alterations
June 2019 Vol 5 No 3 – June 25, 2019
New Developments in Lung Cancer Therapy Reported at Recent Cancer Meetings
Lung CancerNewsworthy
New Developments in Lung Cancer Therapy Reported at Recent Cancer Meetings
By Dana Taylor
November 2018 Volume 4 – Lung Cancer – November 18, 2018
FDA Approvals, News & UpdatesLung CancerNewsworthy
Vizimpro a New First Treatment for Patients with Metastatic Lung Cancer and EGFR Mutations
November 2018 Volume 4 – Lung Cancer – November 17, 2018
Imfinzi First Drug Approved to Reduce Cancer Progression in Stage III Lung Cancer
FDA Approvals, News & UpdatesLung CancerNewsworthy
Imfinzi First Drug Approved to Reduce Cancer Progression in Stage III Lung Cancer
November 2018 Volume 4 – Lung Cancer – November 17, 2018
Gilotrif Approved as First Treatment for Metastatic Lung Cancer and EGFR Mutations
FDA Approvals, News & UpdatesLung CancerNewsworthy
Gilotrif Approved as First Treatment for Metastatic Lung Cancer and EGFR Mutations
November 2018 Volume 4 – Lung Cancer – November 17, 2018
FDA Approvals, News & UpdatesLeukemiaNewsworthy
Tibsovo First Drug Approved by the FDA for AML with IDH1 Mutation
October 2018 Vol 4 No 5 – October 17, 2018
In July 2018, the FDA approved Tibsovo (ivo-sidenib; from Agios Pharmaceuticals), the first IDH1 inhibitor, for the treatment of adults with relapsed (returning) or refractory (not responding to treatment) acute myeloid leukemia (AML) and a susceptible IDH1 genetic mutation.
FDA Approvals, News & UpdatesLung CancerNewsworthy
FDA Approved Opdivo for Metastatic Small-Cell Lung Cancer
October 2018 Vol 4 No 5 – October 17, 2018
Page 1 of 6
Results 1 - 10 of 59

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country